{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,12]],"date-time":"2026-09-12T16:08:45Z","timestamp":1789229325096,"version":"build-2803163510"},"reference-count":50,"publisher":"International Heart Journal (Japanese Heart Journal)","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Int. Heart J."],"published-print":{"date-parts":[[2026,1,31]]},"DOI":"10.1536\/ihj.25-257","type":"journal-article","created":{"date-parts":[[2026,1,30]],"date-time":"2026-01-30T22:09:33Z","timestamp":1769810973000},"page":"43-52","source":"Crossref","is-referenced-by-count":1,"title":["Emerging Trends in Hypertrophic Cardiomyopathy Research"],"prefix":"10.1536","volume":"67","author":[{"given":"Yuanguo","family":"Chen","sequence":"first","affiliation":[{"name":"Department of Cardiovascular Medicine, The Ya&apos;an People&apos;s Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shixi","family":"Luo","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, The Ya&apos;an People&apos;s Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, The Ya&apos;an People&apos;s Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haibo","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, The Ya&apos;an People&apos;s Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"437","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1. Ommen SR, Mital S, Burke MA, <i>et al<\/i>. 2020 AHA\/ACC Guideline for the Diagnosis and Treatment of Patients With Hypertrophic Cardiomyopathy: Executive Summary: A Report of the American College of Cardiology\/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation 2020; 142: e533-57.","DOI":"10.1161\/CIR.0000000000000945"},{"key":"2","doi-asserted-by":"publisher","unstructured":"2. Maron BJ, Gardin JM, Flack JM, Gidding SS, Kurosaki TT, Bild DE. Prevalence of hypertrophic cardiomyopathy in a general population of young adults. Echocardiographic analysis of 4111 subjects in the CARDIA Study. Coronary Artery Risk Development in (Young) Adults. Circulation 1995; 92: 785-9.","DOI":"10.1161\/01.CIR.92.4.785"},{"key":"3","doi-asserted-by":"publisher","unstructured":"3. Maron BJ, Maron MS. Hypertrophic cardiomyopathy. Lancet 2013; 381: 242-55.","DOI":"10.1016\/S0140-6736(12)60397-3"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4. Arbelo E, Protonotarios A, Gimeno JR, <i>et al<\/i>. 2023 ESC Guidelines for the management of cardiomyopathies. Eur Heart J 2023; 44: 3503-626.","DOI":"10.1093\/eurheartj\/ehad194"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5. Maron BJ, Desai MY, Nishimura RA, <i>et al<\/i>. Management of Hypertrophic Cardiomyopathy: JACC State-of-the-Art Review. J Am Coll Cardiol 2022; 79: 390-414.","DOI":"10.1016\/j.jacc.2021.11.021"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6. Wheeler MT, Jacoby D, Elliott PM, <i>et al<\/i>. Effect of beta-blocker therapy on the response to mavacamten in patients with symptomatic obstructive hypertrophic cardiomyopathy. Eur J Heart Fail 2023; 25: 260-70.","DOI":"10.1002\/ejhf.2737"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7. Yokoyama Y, Shimoda T, Shimada YJ, <i>et al<\/i>. Alcohol septal ablation versus surgical septal myectomy of obstructive hypertrophic cardiomyopathy: systematic review and meta-analysis. Eur J Cardiothorac Surg 2023; 63: ezad043.","DOI":"10.1093\/ejcts\/ezad043"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8. Wells S, Rowin EJ, Boll G, <i>et al<\/i>. Clinical Profile of Nonresponders to Surgical Myectomy with Obstructive Hypertrophic Cardiomyopathy. Am J Med 2018; 131: e235-9.","DOI":"10.1016\/j.amjmed.2017.12.031"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9. Rabiee Rad M, Ghasempour Dabaghi G, Habibi D. Safety and efficacy of mavacamten for treatment of hypertrophic cardiomyopathy: a systematic review and meta-analysis of randomized clinical trials. Egypt Heart J 2023; 75: 4.","DOI":"10.1186\/s43044-023-00328-7"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10. Zhou M, Ta S, Hahn RT, <i>et al<\/i>. Percutaneous Intramyocardial Septal Radiofrequency Ablation in Patients With Drug-Refractory Hypertrophic Obstructive Cardiomyopathy. JAMA Cardiol 2022; 7: 529-38.","DOI":"10.1001\/jamacardio.2022.0259"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11. Chen C. Science Mapping: A Systematic Review of the Literature. J Data Inf Sci 2017; 2: 1-40.","DOI":"10.1515\/jdis-2017-0006"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12. Wang H, Shi J, Shi S, Bo R, Zhang X, Hu Y. Bibliometric Analysis on the Progress of Chronic Heart Failure. Curr Probl Cardiol 2022; 47: 101213.","DOI":"10.1016\/j.cpcardiol.2022.101213"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13. Yardibi F, Chen C, Firat MZ, Karacaoren B, Suzen E. The trend of breeding value research in animal science: bibliometric analysis. Arch Anim Breed 2023; 66 (2): 163-81.","DOI":"10.5194\/aab-66-163-2023"},{"key":"14","doi-asserted-by":"publisher","unstructured":"14. Olivotto I, Oreziak A, Barriales-Villa R, Abraham TP, Masri A, Garcia-Pavia P, <i>et al<\/i>. Mavacamten for treatment of symptomatic obstructive hypertrophic cardiomyopathy (EXPLORER-HCM): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet 2020; 396: 759-69.","DOI":"10.1016\/S0140-6736(20)31792-X"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15. Xu G, Jin B, Xian X, <i>et al<\/i>. Evolutions in the Management of Hepatocellular Carcinoma over Last 4 Decades: An Analysis from the 100 Most Influential Articles in the Field. Liver Cancer 2021; 10: 137-50.","DOI":"10.1159\/000513412"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16. Ahmad T, Imran M, Ahmad K, <i>et al<\/i>. A Bibliometric Analysis and Global Trends in Fascioliasis Research: A Neglected Tropical Disease. Animals (Basel) 2021; 11: 3385.","DOI":"10.3390\/ani11123385"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17. Chen H, Luo Y, Zhang X, <i>et al<\/i>. Global research trends of immunosenescence: A bibliometric study. Heliyon 2023; 9: e20362.","DOI":"10.1016\/j.heliyon.2023.e20362"},{"key":"18","doi-asserted-by":"crossref","unstructured":"18. Bukar UA, Sayeed MS, Razak SFA, Yogarayan S, Amodu OA, Mahmood RAR. A method for analyzing text using VOSviewer. MethodsX 2023; 11: 102339.","DOI":"10.1016\/j.mex.2023.102339"},{"key":"19","unstructured":"19. Chen C, Chen Y. Searching for clinical evidence in CiteSpace. AMIA Annu Symp Proc 2005; 2005: 121-5."},{"key":"20","doi-asserted-by":"crossref","unstructured":"20. Chen C, Hu Z, Liu S, Tseng H. Emerging trends in regenerative medicine: a scientometric analysis in CiteSpace. Expert Opin Biol Ther 2012; 12: 593-608.","DOI":"10.1517\/14712598.2012.674507"},{"key":"21","doi-asserted-by":"crossref","unstructured":"21. van Eck NJ, Waltman L. Citation-based clustering of publications using CitNetExplorer and VOSviewer. Scientometrics 2017; 111: 1053-70.","DOI":"10.1007\/s11192-017-2300-7"},{"key":"22","doi-asserted-by":"crossref","unstructured":"22. Hassan-Montero Y, De-Moya-Aneg\u00f3n F, Guerrero-Bote VP. SCImago Graphica: a new tool for exploring and visually communicating data. El Profesional de la informaci\u00f3n 2022; 31: epi.2022.sep.02.","DOI":"10.3145\/epi.2022.sep.02"},{"key":"23","doi-asserted-by":"crossref","unstructured":"23. Qin Y, Zhang Q, Liu Y. Analysis of knowledge bases and research focuses of cerebral ischemia-reperfusion from the perspective of mapping knowledge domain. Brain Res Bull 2020; 156: 15-24.","DOI":"10.1016\/j.brainresbull.2019.12.004"},{"key":"24","doi-asserted-by":"crossref","unstructured":"24. Durieux V, Gevenois PA. Bibliometric indicators: quality measurements of scientific publication. Radiology 2010; 255: 342-51.","DOI":"10.1148\/radiol.09090626"},{"key":"25","doi-asserted-by":"crossref","unstructured":"25. Citro R, Bellino M, Merli E, Di Vece D, Sherrid MV. Obstructive Hypertrophic Cardiomyopathy and Takotsubo Syndrome: How to Deal With Left Ventricular Ballooning? J Am Heart Assoc 2023; 12: e032028.","DOI":"10.1161\/JAHA.123.032028"},{"key":"26","doi-asserted-by":"crossref","unstructured":"26. Soteriades ES, Falagas ME. Comparison of amount of biomedical research originating from the European Union and the United States. BMJ 2005; 331: 192-4.","DOI":"10.1136\/bmj.331.7510.192"},{"key":"27","doi-asserted-by":"crossref","unstructured":"27. Sakai-Bizmark R, Webber EJ, Marr EH, Mena LA, Chang RR. Patient characteristics and incidence of childhood hospitalisation due to hypertrophic cardiomyopathy in the United States of America 2001-2014. Cardiol Young 2019; 29: 344-54.","DOI":"10.1017\/S1047951118002421"},{"key":"28","doi-asserted-by":"crossref","unstructured":"28. Cecchi F, Olivotto I, Montereggi A, Santoro G, Dolara A, Maron BJ. Hypertrophic cardiomyopathy in Tuscany: clinical course and outcome in an unselected regional population. J Am Coll Cardiol 1995; 26: 1529-36.","DOI":"10.1016\/0735-1097(95)00353-3"},{"key":"29","doi-asserted-by":"crossref","unstructured":"29. Baudhuin LM. Hypertrophic Cardiomyopathy in the General Population: Leveraging the UK Biobank Database and Machine Learning Phenotyping. J Am Coll Cardiol 2021; 78: 1111-3.","DOI":"10.1016\/j.jacc.2021.07.036"},{"key":"30","doi-asserted-by":"crossref","unstructured":"30. Gal D, Glanzel W, Sipido KR. Mapping cross-border collaboration and communication in cardiovascular research from 1992 to 2012. Eur Heart J 2017; 38: 1249-58.","DOI":"10.1093\/eurheartj\/ehw459"},{"key":"31","doi-asserted-by":"crossref","unstructured":"31. Oelrich B, Peters R, Jung K. A bibliometric evaluation of publications in urological journals among European Union countries between 2000-2005. Eur Urol 2007; 52: 1238-48.","DOI":"10.1016\/j.eururo.2007.06.050"},{"key":"32","unstructured":"32. Garfield E. Journal impact factor: a brief review. CMAJ 1999; 161: 979-80."},{"key":"33","doi-asserted-by":"crossref","unstructured":"33. He Z, Dai L, Zuo Y, Chen Y, Wang H, Zeng H. Hotspots and frontiers in pulmonary arterial hypertension research: a bibliometric and visualization analysis from 2011 to 2020. Bioengineered 2022; 13: 14667-80.","DOI":"10.1080\/21655979.2022.2100064"},{"key":"34","doi-asserted-by":"publisher","unstructured":"34. Veselka J, Anavekar NS, Charron P. Hypertrophic obstructive cardiomyopathy. Lancet 2017; 389: 1253-67.","DOI":"10.1016\/S0140-6736(16)31321-6"},{"key":"35","doi-asserted-by":"crossref","unstructured":"35. Selzman C. Commentary: Latent hypertrophic obstructive cardiomyopathy-(un)clear and present danger. J Thorac Cardiovasc Surg 2022; 164: 1872-3.","DOI":"10.1016\/j.jtcvs.2020.12.140"},{"key":"36","doi-asserted-by":"crossref","unstructured":"36. Hidalgo LF, Naidu SS, Aronow WS. Pharmacological and non-pharmacological treatment of obstructive hypertrophic cardiomyopathy. Expert Rev Cardiovasc Ther 2018; 16: 21-6.","DOI":"10.1080\/14779072.2018.1417038"},{"key":"37","doi-asserted-by":"crossref","unstructured":"37. Maron MS, Masri A, Choudhury L, <i>et al<\/i>. Phase 2 Study of Aficamten in Patients With Obstructive Hypertrophic Cardiomyopathy. J Am Coll Cardiol 2023; 81: 34-45.","DOI":"10.1016\/j.jacc.2022.10.020"},{"key":"38","doi-asserted-by":"crossref","unstructured":"38. Liu L, Li J, Zuo L, <i>et al<\/i>. Percutaneous Intramyocardial Septal Radiofrequency Ablation for Hypertrophic Obstructive Cardiomyopathy. J Am Coll Cardiol 2018; 72: 1898-909.","DOI":"10.1016\/j.jacc.2018.07.080"},{"key":"39","doi-asserted-by":"crossref","unstructured":"39. Geske JB, Ong KC, Siontis KC, <i>et al<\/i>. Women with hypertrophic cardiomyopathy have worse survival. Eur Heart J 2017; 38: 3434-40.","DOI":"10.1093\/eurheartj\/ehx527"},{"key":"40","doi-asserted-by":"crossref","unstructured":"40. Spertus JA, Fine JT, Elliott P, <i>et al<\/i>. Mavacamten for treatment of symptomatic obstructive hypertrophic cardiomyopathy (EXPLORER-HCM): health status analysis of a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet 2021; 397: 2467-75.","DOI":"10.1016\/S0140-6736(21)00763-7"},{"key":"41","doi-asserted-by":"crossref","unstructured":"41. Ho CY, Mealiffe ME, Bach RG, <i>et al<\/i>. Evaluation of Mavacamten in Symptomatic Patients With Nonobstructive Hypertrophic Cardiomyopathy. J Am Coll Cardiol 2020; 75: 2649-60.","DOI":"10.1016\/j.jacc.2020.03.064"},{"key":"42","doi-asserted-by":"crossref","unstructured":"42. Zhang C, Liu R, Yuan J, <i>et al<\/i>. Predictive Values of N-Terminal Pro-B-Type Natriuretic Peptide and Cardiac Troponin I for Myocardial Fibrosis in Hypertrophic Obstructive Cardiomyopathy. PLoS One 2016; 11: e0146572.","DOI":"10.1371\/journal.pone.0146572"},{"key":"43","doi-asserted-by":"crossref","unstructured":"43. O&apos;Mahony C, Jichi F, Pavlou M, <i>et al<\/i>. A novel clinical risk prediction model for sudden cardiac death in hypertrophic cardiomyopathy (HCM risk-SCD). Eur Heart J 2014; 35: 2010-20.","DOI":"10.1093\/eurheartj\/eht439"},{"key":"44","doi-asserted-by":"crossref","unstructured":"44. Goff ZD, Calkins H. Sudden death related cardiomyopathies - Hypertrophic cardiomyopathy. Prog Cardiovasc Dis 2019; 62: 212-6.","DOI":"10.1016\/j.pcad.2019.04.001"},{"key":"45","doi-asserted-by":"crossref","unstructured":"45. Miron A, Lafreniere-Roula M, Steve Fan CP, <i>et al<\/i>. A Validated Model for Sudden Cardiac Death Risk Prediction in Pediatric Hypertrophic Cardiomyopathy. Circulation 2020; 142: 217-29.","DOI":"10.1161\/CIRCULATIONAHA.120.047235"},{"key":"46","doi-asserted-by":"crossref","unstructured":"46. Trivedi A, Knight BP. ICD Therapy for Primary Prevention in Hypertrophic Cardiomyopathy. Arrhythm Electrophysiol Rev 2016; 5: 188-96.","DOI":"10.15420\/aer.2016:30:2"},{"key":"47","doi-asserted-by":"crossref","unstructured":"47. Sedaghat-Hamedani F, Kayvanpour E, Tugrul OF, <i>et al<\/i>. Clinical outcomes associated with sarcomere mutations in hypertrophic cardiomyopathy: a meta-analysis on 7675 individuals. Clin Res Cardiol 2018; 107: 30-41.","DOI":"10.1007\/s00392-017-1155-5"},{"key":"48","doi-asserted-by":"crossref","unstructured":"48. Bos JM, Will ML, Gersh BJ, Kruisselbrink TM, Ommen SR, Ackerman MJ. Characterization of a phenotype-based genetic test prediction score for unrelated patients with hypertrophic cardiomyopathy. Mayo Clin Proc 2014; 89: 727-37.","DOI":"10.1016\/j.mayocp.2014.01.025"},{"key":"49","doi-asserted-by":"crossref","unstructured":"49. Reichart D, Newby GA, Wakimoto H, <i>et al<\/i>. Efficient <i>in vivo<\/i> genome editing prevents hypertrophic cardiomyopathy in mice. Nat Med 2023; 29: 412-21.","DOI":"10.1038\/s41591-022-02190-7"},{"key":"50","doi-asserted-by":"crossref","unstructured":"50. Smith N, Steeds R, Masani N, <i>et al<\/i>. A systematic approach to echocardiography in hypertrophic cardiomyopathy: a guideline protocol from the British Society of Echocardiography. Echo Res Pract 2015; 2: G1-7.","DOI":"10.1530\/ERP-14-0115"}],"container-title":["International Heart Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/ihj\/67\/1\/67_25-257\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,31]],"date-time":"2026-01-31T04:11:58Z","timestamp":1769832718000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/ihj\/67\/1\/67_25-257\/_article"}},"subtitle":["A Comprehensive Bibliometric and Visualization Analysis, 2013-2023"],"short-title":[],"issued":{"date-parts":[[2026,1,31]]},"references-count":50,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.1536\/ihj.25-257","relation":{},"ISSN":["1349-2365","1349-3299"],"issn-type":[{"value":"1349-2365","type":"print"},{"value":"1349-3299","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,31]]},"article-number":"25-257"}}